The ABCD Exenatide Audit

C Walton on behalf of ABCD Exenatide Audit Contributors

Hull Royal Infirmary, Hull, UK

The Association of British Clinical Diabetologists nationwide exenatide and liraglutide audits suggest a low incidence of acute pancreatitis. Response to Robson. Incretins and pancreatitis—what happens next? A personal viewpoint

R. E. J. Ryder¹, P. Sen Gupta^1,2, K. Y. Thong¹ on behalf of the ABCD nationwide exenatide^* and liraglutide^† audit contributors

¹Department of Diabetes and Endocrinology, City Hospital, Birmingham, UK

²Diabetes Research Group, King’s College, London, UK

Was it really pancreatitis from GLP-1 receptor agonist therapy?

KY Thong¹, REJ Ryder¹ on behalf of the ABCD nationwide exenatide audit contributors²

¹Department of Diabetes, Endocrinology and Lipids Metabolism, City Hospital, Birmingham, UK

²ABCD nationwide exenatide audit contributors reference 6

Incidence of acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

REJ Ryder¹ and KY Thong² on behalf of the ABCD nationwide exenatide audit contributors³

¹Clinical Lead, ABCD Nationwide Audits; Consultant Physician (Diabetes), City Hospital, Birmingham, UK.

²Formerly Research Fellow, ABCD Nationwide Audits; Consultant Physician and Endocrinologist, Rockingham General Hospital, Perth, Western Australia.

Findings from the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

REJ Ryder¹ and KY Thong¹, on behalf of the ABCD nationwide exenatide and nationwide liraglutide audit contributors^†

¹City Hospital, Birmingham, UK

^†List of ABCD nationwide exenatide audit contributors

Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

K. Y. Thong¹ , R. E. J. Ryder¹ , M. L. Cull¹ and C. Walton² on behalf of the ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

²Diabetes, Hull Royal Infirmary, Hull, UK

Response at 3 months to insulin dose decisions made at exenatide initiation in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

K.Y. Thong ^a,1, B. Jose ^a,1, A.D. Blann ^a,1, M.L. Cull ^a,1, A.P. Mills^a,1 , T. Sathyapalan^b,1 , C. Walton^b,1 , R.E.J. Ryder^a,1 On behalf of the ABCD nationwide exenatide contributors^†

^aCity Hospital, Birmingham, United Kingdom

^bHull Royal Infirmary, Hull, United Kingdom

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

K. Y. Thong¹, B. Jose¹, N. Sukumar¹, M. L. Cull¹, A. P. Mills¹, T. Sathyapalan², W. Shafiq², A. S. Rigby², C. Walton² & R. E. J. Ryder¹ on behalf of the ABCD nationwide exenatide audit contributors^†

¹Department of Diabetes, City Hospital, Birmingham, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

REJ Ryder¹, KY Thong¹, ML Cull¹, AP Mills¹, C Walton², PH Winocour³ on behalf of the ABCD nationwide exenatide audit contributors^†

¹City Hospital, Birmingham, UK

²Hull Royal Infirmary, Hull, UK

³Queen Elizabeth II Hospital, Welwyn Garden City, UK

^†Appendix 1, List of Contributors in the ABCD Nationwide Exenatide Audit